In summary, our data identify FoxP1 as a novel transcriptional repressor of skeletal muscle gene expression that is up‐regulated in multiple models of cancer cachexia and in muscle of cachectic cancer patients that is sufficient to induce features of cachexia, including body mass loss, muscle wasting and weakness, and impaired muscle regeneration. This evidence concerns the gene FOXP1 and cancer.